Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

Exclusion Criteria

• •1. Multicentricity in various quadrants (contact the study office)
• •2. CNS-metastases
• •3. Secondary malignancy, excluding basalioma of the skin or carcinoma in situ of the cervix that has received curative therapy
• •4. Patients with relevant hemodynamic cardial diseases
• •5. Patients with a left ventricular ejection fraction (LVEF) under the normal limit of the institution, confirmed by echocardiography or MUGA-Scan.
• •6. Uncontrolled, severe comorbidities
• •7. Patients with severe respiratory diseases and severe dyspnea and / or which need supportive oxygen
• •8. Previous anti-HER2-therapy
• •9. Patients receiving immunosuppressant therapy
• •10. Known allergy to medication containing cremophor
• •11. Hb \<10 g/dL, Neutrophile \<1.5 x109/L, Thrombocytes \<100 x109/L.
• •12. Total-Serum-Bilirubin \>1.5 x ULN (upper limit of normal) (except in patients with confirmed and documented Gilbert-Lereboullet-syndrome), ALT or AST \>2.5 x ULN (\>5 x ULN by liver metastases), Alkaline Phosphatase \>2.5 x ULN (\>4 x ULN by liver or bone metastases), Serumcreatinine \> 2 x ULN
• •13. Pregnancy, nursing (a negative pregnancy test must be documented, and safe anticontraceptive measures during pre- and postoperative treatment must be implemented)
• •14. Lack of signed informed consent after informing the patient
• •15. Lack of willingness to keep and disclose personal medical data as part of the study